|
Real-time Estimate
Cboe BZX
10:52:31 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 2.730 USD | +5.81% |
|
+5.53% | +64.45% |
| 10-06 | Guggenheim Initiates Ovid Therapeutics at Buy | MT |
| 09-20 | Ovid Therapeutics Inc.(NasdaqCM:OVID) added to S&P Global BMI Index | CI |
| Market Cap | 504M 449M 411M 374M 705M 47.62B 724M 4.93B 1.97B 25.22B 1.89B 1.85B 79.57B | P/E 2026 * |
-7.15x | P/E 2027 * | -6.69x |
|---|---|---|---|---|---|
| Enterprise Value | 377M 336M 307M 280M 527M 35.61B 542M 3.69B 1.48B 18.86B 1.41B 1.38B 59.52B | EV / Sales 2026 * |
476x | EV / Sales 2027 * | 530x |
| Free-Float |
93.28% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| OVID | Delayed | |
CBOE
| OVID | Real-time | |
|
Tradegate
| 1OT | Real-time | |
|
Deutsche Boerse AG
| 1OT | Delayed | |
|
Börse Stuttgart
| 1OT | Delayed | |
|
Boerse Muenchen
| 1OT | Real-time |
Last Transcript: Ovid Therapeutics Inc.
| 1 day | +5.81% | ||
| 1 week | +5.53% | ||
| Current month | +5.53% | ||
| 1 month | +13.10% | ||
| 3 months | +1.15% | ||
| 6 months | -3.58% | ||
| Current year | +64.45% |
| 1 week | 2.37 |  | 2.79 |
| 1 month | 2.09 | | 2.79 |
| Current year | 1.36 | | 3.1 |
| 1 year | 1.18 | | 3.1 |
| 3 years | 0.24 | | 4.1 |
| 5 years | 0.24 | | 4.14 |
| 10 years | 0.24 | | 15.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 45 | 2025-12-31 | |
Charles Carter
DFI | Director of Finance/CFO | 59 | 2026-07-05 |
Petra Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 60 | 2025-12-01 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeremy Levin
CHM | Chairman | 72 | 2014-03-31 |
Bart Friedman
BRD | Director/Board Member | 81 | 2015-11-22 |
Barbara Duncan
BRD | Director/Board Member | 61 | 2017-06-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/6/26 | Free | Chief Financial Officer | 50,000 | 0.0268% | ||
| 7/6/26 | Other | Chief Financial Officer | 450,625 | 0.2414% | ||
| 4/7/26 | Free | Director | 17,578 | 0.0133% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.81% | +5.53% | +101.54% | -17.52% | 504M | |
| -4.83% | +2.88% | +55.87% | +69.12% | 69.4B | |
| -0.81% | +0.20% | +9.68% | +75.14% | 57.24B | |
| -1.00% | +2.92% | +24.72% | +100.06% | 57.62B | |
| +2.21% | +0.91% | +27.94% | +35.97% | 43.65B | |
| +4.62% | +9.69% | +22.22% | +107.10% | 44.03B | |
| +4.90% | -3.14% | +201.89% | +760.26% | 38.08B | |
| -1.86% | +11.46% | +26.67% | +61.40% | 36.31B | |
| -3.01% | -10.28% | +87.95% | +75.32% | 32.61B | |
| -2.18% | +5.68% | +36.21% | -0.69% | 25.47B | |
| Average | +0.36% | +2.09% | +59.47% | +126.62% | 40.49B | |
| Weighted average by Cap. | -0.44% | +2.43% | +50.75% | +135.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 792K 705K 645K 588K 1.11M 74.81M 1.14M 7.75M 3.1M 39.62M 2.97M 2.91M 125M | 326K 290K 265K 242K 456K 30.77M 468K 3.19M 1.27M 16.3M 1.22M 1.2M 51.42M |
| Net income | -66.32M -59.1M -54.06M -49.23M -92.8M -6.27B -95.3M -649M -260M -3.32B -249M -244M -10.47B | -83.13M -74.08M -67.76M -61.71M -116M -7.86B -119M -814M -326M -4.16B -312M -305M -13.13B |
| Net Debt | -127M -113M -104M -94.27M -178M -12B -182M -1.24B -497M -6.36B -477M -466M -20.06B | -331M -295M -270M -246M -463M -31.3B -476M -3.24B -1.3B -16.58B -1.24B -1.22B -52.31B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-06 | US$2.685 | +4.07% | 247,545 |
| 26-11-05 | US$2.580 | -5.84% | 2,016,184 |
| 26-11-04 | US$2.740 | +14.17% | 3,610,175 |
| 26-11-03 | US$2.400 | +0.42% | 1,375,088 |
| 26-11-02 | US$2.390 | -5.91% | 2,337,026 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- OVID Stock
Select your edition
All financial news and data tailored to specific country editions
